Toggle Main Menu Toggle Search

Open Access padlockePrints

Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Lookup NU author(s): Dr Ian Griffiths

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Background Patients with rheumatoid arthritis (RA) have an increased risk of certain solid cancers, in particular lung cancer, compared to the general population. Treatment with tumour necrosis factor (TNF) inhibitors (TNFi) may further enhance this risk. Objectives To compare the risk of solid cancer in patients with RA treated with TNFi to that in patients treated with non-biologic (synthetic) disease modifying antirheumatic drugs (sDMARDs). Methods Patients with a physician diagnosis of RA enrolled in the British Society for Rheumatology Biologics Register, a national prospective cohort study established in 2001 to monitor the long-term safety of TNFi, were followed via record linkage with the national cancer registries until first solid cancer, death, for 5 years, or until 2011. Rates of solid cancers in 11 767 patients without prior cancer who received TNFi were compared to those in 3249 patients without prior cancer treated with sDMARDs. Results 427 solid cancers were reported in 52 549 patient-years follow-up for the TNFi group (81 (95% CI 74 to 89) per 10 000 patient-years) and 136 cancers were reported in 11 672 patient-years in the sDMARD cohort (117 (95% CI 98 to 138) per 10 000 patientyears). After adjusting for differences in baseline characteristics there was no difference in risk of solid cancer for TNFi compared to sDMARD treated patients: HR 0.83 (95% CI 0.64 to 1.07). There was no difference in the relative risk of cancer for any of the individual TNFi drugs. Conclusions The addition of TNFi to sDMARD does not alter the risk of cancer in RA patients selected for TNFi in the UK.


Publication metadata

Author(s): Mercer LK, Lunt M, Low ALS, Dixon WG, Watson KD, Symmons DPM, Hyrich KL, Maiden N, Price T, Hopkinson N, O'Reilly S, Hordon L, Griffiths I, Porter D, Madhok R, Hassell A, Cooper RG, Choy E, Walsh D, Emery P, Knight S, Bruce I, Taggart A, Scott D, Thompson P, McCrae F, Goodfellow R, Kitas G, Jubb R, Abernethy R, Green S, Sanders P, Coulson A, Harrison B, Bukhari M, Klimiuk P

Publication type: Article

Publication status: Published

Journal: Annals of the Rheumatic Diseases

Year: 2015

Volume: 74

Issue: 6

Pages: 1087-1093

Print publication date: 01/06/2015

Online publication date: 31/03/2014

Acceptance date: 01/03/2014

ISSN (print): 0003-4967

ISSN (electronic): 1468-2060

Publisher: BMJ Publishing Group

URL: http://doi.org/10.1136/annrheumdis-2013-204851

DOI: 10.1136/annrheumdis-2013-204851

PubMed id: 24685910


Altmetrics

Altmetrics provided by Altmetric


Share